Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px
Document › Details

GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris.

Organisations Organisation GenSight Biologics S.A. (Euronext: SIGHT)
  Organisation 2 Sofinnova Partners SAS
  Group Sofinnova (Group)
Products Product gene therapy eye disease
  Product 2 investment banking
Index term Index term GenSight Biologics–SEVERAL: investment, 202311 private + public offerings totalling €4.7m
Person Person Gilly, Bernard (GenSight Biologics 201304 CEO + Co-founder before Fovea + Sofinnova Partners + Transgene)
     


   
Record changed: 2024-02-12

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top